ArticleArchives of microbiology2025
In vitro anti-Helicobacter pylori activity and phenotypic screening of novel quinolone compounds.
Article in Archives of microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Helicobacter pylori (H. pylori) is a widespread pathogen and a significant causative agent of chronic gastritis and peptic ulcers. However, eradication rates are declining rapidly because of increasing antibiotic resistance, and recurrence rates are rising. Quinolone-based regimens were once considered effective treatment options; however, their clinical utility has been substantially limited in recent years by a marked increase in resistance rates worldwide. Therefore, the development of more effective drugs and treatment strategies is crucial for combating H. pylori infections. This study evaluated the in vitro antibacterial activity and cytotoxicity of a series of novel quinolone compounds (provided by the team of Professor Ying-Qian Liu from the School of Pharmacy, Lanzhou University), ultimately identifying two lead compounds, ET-8 and ET-30, for further investigation, with minimum inhibitory concentrations (MICs) of 5.29 micromolar (µM) and 5.20 µM, respectively. Furthermore, ET-8 and ET-30 were also effective against both sensitive and resistant strains of H. pylori. Investigations involving urease inhibition assays, transmission electron microscopy, and adhesion assays suggested that ET-8 and ET-30 likely exert their antibacterial effects by disrupting bacterial morphology, inhibiting adhesion and colonization, and suppressing urease activity. Additionally, RT‒qPCR analysis revealed that these phenotypic changes were accompanied by the downregulation of key virulence and adhesion genes (vacA, cagA, sabA, and babA); however, this correlation does not establish causation, providing a compelling mechanistic hypothesis for the observed antibacterial effects. Collectively, these findings demonstrate that compared with the current fluoroquinolone therapeutic, levofloxacin (LEV), ET-8 and ET-30 exhibit superior antibacterial activity and a more favorable safety profile, highlighting their strong potential as candidate agents for future anti-H. pylori therapies.
Indexed as
Identifiers
41264022What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.